PMC:7321036 / 46546-46720
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T372 | 8-13 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T228 | 153-161 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T229 | 164-173 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T569 | 0-13 | http://purl.obolibrary.org/obo/CLO_0051719 | denotes | Vero E6 cells |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T325 | 31-44 | Chemical | denotes | AXL inhibitor | http://purl.obolibrary.org/obo/CHEBI_62434 |
T326 | 35-44 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T327 | 45-57 | Chemical | denotes | gilteritinib | http://purl.obolibrary.org/obo/CHEBI_145372 |
T328 | 77-86 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T329 | 118-127 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
962 | 31-34 | Gene | denotes | AXL | Gene:103234725 |
963 | 67-76 | Gene | denotes | MAPK11/14 | Gene:103223551 |
964 | 111-117 | Gene | denotes | MAPK13 | Gene:103221595 |
965 | 128-134 | Gene | denotes | MAPK13 | Gene:103221595 |
966 | 45-57 | Chemical | denotes | gilteritinib | MESH:C000609080 |
967 | 87-98 | Chemical | denotes | ralimetinib | |
968 | 153-173 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
969 | 5-7 | CellLine | denotes | E6 | CVCL:4582 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T311 | 0-174 | Sentence | denotes | Vero E6 cells treated with the AXL inhibitor gilteritinib (E), the MAPK11/14 inhibitor ralimetinib (F), or the MAPK13 inhibitor MAPK13-IN-1 (G) prior to SARS-CoV-2 infection. |